
Chien-Yuan Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8536934/publications.pdf Version: 2024-02-01



CHIEN-YHAN CHEN

#	Article	IF	CITATIONS
1	AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood, 2009, 114, 5352-5361.	0.6	318
2	TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood, 2011, 118, 3803-3810.	0.6	272
3	DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood, 2012, 119, 559-568.	0.6	211
4	Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells. Clinical Cancer Research, 2005, 11, 1372-1379.	3.2	202
5	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010, 115, 2749-2754.	0.6	193
6	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood, 2010, 116, 4086-4094.	0.6	187
7	Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. Cancer Research, 2006, 66, 3310-3316.	0.4	165
8	WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood, 2010, 115, 5222-5231.	0.6	156
9	The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood, 2012, 120, 3106-3111.	0.6	127
10	<i>RUNX1</i> gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. British Journal of Haematology, 2007, 139, 405-414.	1.2	122
11	SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes and Cancer, 2003, 37, 300-305.	1.5	108
12	Invasive fungal sinusitis in patients with hematological malignancy: 15 years experience in a single university hospital in Taiwan. BMC Infectious Diseases, 2011, 11, 250.	1.3	98
13	Splicing factor mutations predict poor prognosis in patients with <i>de novo</i> acute myeloid leukemia. Oncotarget, 2016, 7, 9084-9101.	0.8	77
14	<i>IDH</i> mutations are closely associated with mutations of <i>DNMT3A</i> , <i>ASXL1</i> and <i>SRSF2</i> in patients with myelodysplastic syndromes and are stable during disease evolution. American Journal of Hematology, 2014, 89, 137-144.	2.0	76
15	Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematology,the, 2015, 2, e417-e426.	2.2	64
16	Intracranial hemorrhage in adult patients with hematological malignancies. BMC Medicine, 2012, 10, 97.	2.3	58
17	Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood, 2013, 121, 3172-3180.	0.6	58
18	Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 2013, 88, E277-82.	2.0	56

CHIEN-YUAN CHEN

#	Article	IF	CITATIONS
19	Clinical implications of the <i>SETBP1</i> mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 2014, 89, 181-186.	2.0	56
20	Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leukemia Research, 2008, 32, 904-912.	0.4	55
21	Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Annals of Hematology, 2014, 93, 1371-1380.	0.8	54
22	Clinical and Microbiological Characteristics of Perianal Infections in Adult Patients with Acute Leukemia. PLoS ONE, 2013, 8, e60624.	1.1	48
23	Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer, 2015, 15, 344.	1.1	48
24	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2019, 19, 617.	1.1	43
25	Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008–2013. International Journal of Antimicrobial Agents, 2017, 49, 272-281.	1.1	41
26	Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. Blood Cancer Journal, 2017, 7, 663.	2.8	39
27	Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies. BMC Infectious Diseases, 2011, 11, 324.	1.3	38
28	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clinical Epigenetics, 2018, 10, 42.	1.8	36
29	<i>SF3B1</i> mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution. American Journal of Hematology, 2014, 89, E109-15.	2.0	34
30	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. Blood Cancer Journal, 2018, 8, 87.	2.8	34
31	Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. Journal of the Formosan Medical Association, 2004, 103, 526-32.	0.8	34
32	Clinical implications of SOCS1 methylation in myelodysplastic syndrome. British Journal of Haematology, 2006, 135, 317-323.	1.2	32
33	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poorâ€risk factor in <i>de novo</i> acute myeloid leukemia patients. European Journal of Haematology, 2018, 101, 86-94.	1.1	31
34	Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001–2010. International Journal of Antimicrobial Agents, 2012, 40, 533-538.	1.1	30
35	Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i> . Haematologica, 2018, 103, e510-e513.	1.7	29
36	Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). Cancer Letters, 2016, 376, 218-225.	3.2	28

CHIEN-YUAN CHEN

#	Article	IF	CITATIONS
37	Clinical features of patients with infections caused by Candida guilliermondii and Candida fermentati and antifungal susceptibility of the isolates at a medical centre in Taiwan, 2001-10. Journal of Antimicrobial Chemotherapy, 2013, 68, 2632-2635.	1.3	24
38	Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008–2013. Journal of Microbiology, Immunology and Infection, 2020, 53, 106-114.	1.5	24
39	GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution. Annals of Hematology, 2015, 94, 211-221.	0.8	23
40	Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. Leukemia Research, 2014, 38, 1278-1284.	0.4	22
41	High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS ONE, 2015, 10, e0126037.	1.1	21
42	Clinical characteristics and treatment outcomes of patients with candidaemia due to <i>Candida parapsilosis sensu lato</i> species at a medical centre in Taiwan, 2000–12. Journal of Antimicrobial Chemotherapy, 2015, 70, 1531-1538.	1.3	21
43	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget, 2016, 7, 63177-63188.	0.8	21
44	Loss of CD7, independent of galectinâ€3 expression, implies a worse prognosis in adult Tâ€cell leukaemia/lymphoma. Histopathology, 2009, 54, 214-220.	1.6	20
45	Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterology, 2018, 18, 6.	0.8	20
46	Chronic disseminated candidiasis manifesting as hepatosplenic abscesses among patients with hematological malignancies. BMC Infectious Diseases, 2019, 19, 635.	1.3	19
47	MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine. Medical Oncology, 2015, 32, 206.	1.2	18
48	Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation. Scientific Reports, 2016, 6, 36730.	1.6	18
49	IPSSâ€R in 555 <scp>Taiwanese</scp> patients with primary MDS: Integration of monosomal karyotype can better riskâ€stratify the patients. American Journal of Hematology, 2014, 89, E142-9.	2.0	16
50	Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence—clinical implication and comparison between the West and the East. Annals of Hematology, 2013, 92, 799-806.	0.8	14
51	Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia. Leukemia Research, 2019, 81, 95-97.	0.4	12
52	Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis. BMC Cancer, 2013, 13, 107.	1.1	11
53	MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia. Leukemia Research, 2014, 38, 625-631.	0.4	11
54	Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan. Journal of Antimicrobial Chemotherapy, 2006, 57, 1181-1188.	1.3	10

CHIEN-YUAN CHEN

#	Article	IF	CITATIONS
55	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. Bone Marrow Transplantation, 2022, 57, 95-105.	1.3	8
56	Clinical Characteristics and Treatment Response of Hodgkin's Lymphoma in Taiwan. Journal of the Formosan Medical Association, 2008, 107, 4-12.	0.8	6
57	Clinical and Prognostic Implications of Roundabout 4 (Robo4) in Adult Patients with Acute Myeloid Leukemia. PLoS ONE, 2015, 10, e0119831.	1.1	6
58	Deciphering the Role of Pyrvinium Pamoate in the Generation of Integrated Stress Response and Modulation of Mitochondrial Function in Myeloid Leukemia Cells through Transcriptome Analysis. Biomedicines, 2021, 9, 1869.	1.4	6
59	Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation. Cancer Gene Therapy, 2022, 29, 784-792.	2.2	4
60	AML1/RUNX1 Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations Blood, 2009, 114, 1564-1564.	0.6	3
61	Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia — A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy. Blood, 2013, 122, 5214-5214.	0.6	3
62	Characterization of Acute Myeloid Leukemia with PTPN11 Mutation - The Mutation Is Closely Associated with NPM1 Mutation but Inversely Related to FLT3/ITD Blood, 2007, 110, 3490-3490.	0.6	2
63	A rarely considered diagnosis of unknown fever, disseminated lymphadenopathy and chronic peritonitis in Taiwan: Whipple's disease. Journal of Microbiology, Immunology and Infection, 2017, 50, 401-402.	1.5	1
64	Clinical and Biological Characterization of Adult Patients with Acute Myeloid Leukemia Bearing T(7;11)(p15;p15)—Analysis of 536 Patients. Blood, 2008, 112, 2535-2535.	0.6	1
65	Pyrvinium Pamoate Overcomes Cabozantinib-Resistance of FLT3-ITD AML Cells through Modulating the Mitochondria Functions and Signaling Pathways. Blood, 2018, 132, 4683-4683.	0.6	1
66	Gene Mutations, Their Interactions and Associations with Immunophenotypes of Leukemia Cells in Patients with Primary Acute Myeloid Leukemia Blood, 2007, 110, 4138-4138.	0.6	0
67	Hierarchical Cluster Analysis of Immunophenotype in AML Patients with NPM1 Gene Mutation Reveals Two Distinct Groups with Different Prognosis Blood, 2008, 112, 1495-1495.	0.6	0
68	Role of Gene Mutations in Adult Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2009, 114, 3373-3373.	0.6	0
69	Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia. Blood, 2015, 126, 4956-4956.	0.6	Ο
70	Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome. Blood, 2016, 128, 49-49.	0.6	0